Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients... 125 38 38 5 5 Dr. F. S. Nielsen L. N. JØrgensen M. Ipsen A. I. Voldsgaard H. -H. Parving Steno Diabetes Center Niels Steensens Vej 2 DK-2820 Gentofte Denmark Novo Nordisk A. S. BagsvÆrd Denmark Summary Recombinant DNA technology allows the production of insulin analogues with faster absorption rates from subcutaneous tissue as compared to soluble human insulin. The human insulin analogue B10Asp (mono/dimeric) is absorbed twice as fast as soluble human insulin (hexameric). A double blind, randomised crossover study with a 1-month run-in period and two 2-month treatment periods was performed in 21 male insulin-dependent diabetic (IDDM) patients aged 18–40 years in order to compare the metabolic control obtained with equimolar doses of the analogue B10Asp vs soluble human insulin (Actrapid) given as mealtime insulin and intermediate acting isophane insulin (Protaphane) at bedtime. At the end of each 2-month study period, the patients were admitted to the metabolic ward. We found significantly higher plasma insulin/analogue levels after breakfast, lunch and dinner with B10Asp as compared to Actrapid ( p <0.05). The plasma insulin/analogue levels were significantly lower before lunch and dinner with B10Asp as compared to Actrapid ( p <0.05). Also, the plasma insulin/analogue level tended to be lower at bedtime when comparing B10Asp to Actrapid. The 24-h blood glucose profiles showed identical fasting blood glucose, significantly lower blood glucose after breakfast with the analogue ( p <0.05), no differences in blood glucose after lunch and dinner but a significantly higher blood glucose at midnight using the analogue ( p <0.05). The overall 24-h mean blood glucose concentrations, the daily insulin dose, HbA 1c , diet, home blood glucose monitoring and frequency of hypoglycaemia were almost identical in the two treatment periods. In conclusion, the overall glycaemic control remained unchanged and quite good when Actrapid was exchanged dose for dose with the insulin analogue B10Asp in IDDM patients treated with a basal bolus regime. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Diabetologia Springer Journals

Long-term comparison of human insulin analogue B10Asp and soluble human insulin in IDDM patients on a basal/bolus insulin regimen

Loading next page...
 
/lp/springer-journals/long-term-comparison-of-human-insulin-analogue-b10asp-and-soluble-YhissMTOmu

References (43)

Publisher
Springer Journals
Copyright
Copyright © 1995 by Springer-Verlag
Subject
Medicine & Public Health; Human Physiology; Internal Medicine; Metabolic Diseases
ISSN
0012-186X
eISSN
1432-0428
DOI
10.1007/BF00400729
Publisher site
See Article on Publisher Site

Abstract

125 38 38 5 5 Dr. F. S. Nielsen L. N. JØrgensen M. Ipsen A. I. Voldsgaard H. -H. Parving Steno Diabetes Center Niels Steensens Vej 2 DK-2820 Gentofte Denmark Novo Nordisk A. S. BagsvÆrd Denmark Summary Recombinant DNA technology allows the production of insulin analogues with faster absorption rates from subcutaneous tissue as compared to soluble human insulin. The human insulin analogue B10Asp (mono/dimeric) is absorbed twice as fast as soluble human insulin (hexameric). A double blind, randomised crossover study with a 1-month run-in period and two 2-month treatment periods was performed in 21 male insulin-dependent diabetic (IDDM) patients aged 18–40 years in order to compare the metabolic control obtained with equimolar doses of the analogue B10Asp vs soluble human insulin (Actrapid) given as mealtime insulin and intermediate acting isophane insulin (Protaphane) at bedtime. At the end of each 2-month study period, the patients were admitted to the metabolic ward. We found significantly higher plasma insulin/analogue levels after breakfast, lunch and dinner with B10Asp as compared to Actrapid ( p <0.05). The plasma insulin/analogue levels were significantly lower before lunch and dinner with B10Asp as compared to Actrapid ( p <0.05). Also, the plasma insulin/analogue level tended to be lower at bedtime when comparing B10Asp to Actrapid. The 24-h blood glucose profiles showed identical fasting blood glucose, significantly lower blood glucose after breakfast with the analogue ( p <0.05), no differences in blood glucose after lunch and dinner but a significantly higher blood glucose at midnight using the analogue ( p <0.05). The overall 24-h mean blood glucose concentrations, the daily insulin dose, HbA 1c , diet, home blood glucose monitoring and frequency of hypoglycaemia were almost identical in the two treatment periods. In conclusion, the overall glycaemic control remained unchanged and quite good when Actrapid was exchanged dose for dose with the insulin analogue B10Asp in IDDM patients treated with a basal bolus regime.

Journal

DiabetologiaSpringer Journals

Published: May 1, 1995

There are no references for this article.